This inventor holds 1 USPTO granted patent. Top assignee: Resolution Pharmaceutical Inc.. Active years: 1996.
Company Filing History:
Years Active: 1996
Title: Alfred Pollack: Innovator in Radionuclide Chelating Compounds
Introduction
Alfred Pollack is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of radionuclide chelating compounds. His work focuses on the development of innovative solutions for medical diagnostics and therapy.
Latest Patents
Alfred Pollack holds a patent for "Hydrazino-type N.sub.2 S.sub.2 chelators." This invention provides radionuclide chelating compounds that can be conjugated to targeting molecules such as proteins, peptides, or antibodies. The resulting labeled targeting molecules have potential applications in both diagnosis and therapy.
Career Highlights
Pollack is associated with Resolution Pharmaceutical Inc., where he continues to advance his research and development efforts. His expertise in the field has led to the creation of valuable medical technologies.
Collaborations
He has collaborated with notable colleagues, including Robert A. Kirby and Robert Dufault. These partnerships have contributed to the success of his projects and innovations.
Conclusion
Alfred Pollack's work in radionuclide chelating compounds exemplifies the impact of innovation in medical science. His contributions are paving the way for advancements in diagnosis and therapy.